PRGO — Perrigo Company plc

Summary of Perrigo (PRGO) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025:
  • All-In operating income grew by 2%, with EPS at $2.75, aligning with revised guidance.
  • CORE Perrigo operating income increased by 7%, with CORE EPS up 14%.
• Q4 2025:
  • CORE Organic net sales declined by 2%, with CORE operating income down by $4 million (2%), resulting in CORE EPS of $0.76, a decrease of $0.02.
  • All-In net sales and operating income were impacted by divestitures, particularly in the Infant Formula segment, which saw a 25% decline in Q4 sales.
• Cash Position: Ended 2025 with $532 million in cash and operating cash flow of $239 million for the year. Net leverage ratio was 4x.

2. Strategic Updates and Business Highlights

• Three-S Plan: Progress made in simplifying, streamlining, and strengthening the business. Key achievements included stabilizing the store brand business and improving supply in Infant Formula.
• Market Share Gains: Despite a challenging OTC market, Perrigo gained significant market share, particularly in store brands, with over $100 million in new distribution.
• New Reporting Segments: Transitioning to new reporting segments (Self-care, Specialty Care, and Infant Formula) starting Q1 2026 to enhance transparency and align with the global operating model.

3. Forward Guidance and Outlook

• 2026 Outlook:
  • CORE Perrigo organic net sales growth expected to range from -3.5% to +0.5%. CORE EPS forecasted between $2.25 and $2.55.
  • Anticipated challenges in the first half of 2026 due to a soft cough and cold season, with expectations for improvement in the second half.
  • All-In net sales growth projected between -5.5% and -1.5%, with EPS expected in the range of $2 to $2.30.

4. Bad News, Challenges, or Points of Concern

• Infant Formula Segment: Continued structural challenges leading to significant sales declines and a strategic review of the segment.
• Market Conditions: The OTC market is experiencing negative consumption trends, with a 5.1% decline in the U.S. OTC market over the last 13 weeks.
• Goodwill Impairment: A noncash goodwill impairment charge of $1.3 billion recorded for 2025, with potential additional charges of up to $350 million expected in Q1 2026.
• Operational Challenges: Temporary under-absorption of production capacity is expected to negatively impact EPS by approximately $0.60 in 2026.

5. Notable Q&A Insights

• Second Half Recovery: Management expressed confidence in a second half recovery driven by share growth, innovation, and demand generation efforts.
• Liquidity and Leverage: The company plans to use proceeds from the Dermacosmetics divestiture for debt reduction while maintaining dividend commitments.
• Infant Formula Strategy: Ongoing strategic review to assess operational optimization and potential partnerships or divestments, with a focus on improving cash flow generation.
• Margin Recovery: Margins in the OTC business are under pressure due to under-absorption but are expected to normalize as market conditions improve.

This summary encapsulates the key aspects of Perrigo's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.